Royal Bank of Canada
RGC icon

Royal Bank of Canada’s Regencell Bioscience RGC Stock Holding History

Royal Bank of Canada’s Portfolio RGC Stock Details RGC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-69
Closed -$2K – 7735
2026
Q1 		$2K Buy
+69
New +$1.95K ﹤0.01% 6750
2025
Q2 		– Sell
-36,024
Closed -$30K – 7295
2025
Q1 		$30K Buy
+36,024
New +$9.95K ﹤0.01% 5778

Other funds holding RGC

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Amundi
Amundi Paris, France $416B AUM 44.19% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return

Royal Bank of Canada's RGC Position: Q2 2026 in Review

Royal Bank of Canada sold out of Regencell Bioscience (RGC) in Q2 2026, closing a stake of 69 shares — an estimated $2K sold.

Royal Bank of Canada first reported a position in RGC in Q1 2025 and held it in 2 quarters. The position peaked at $30K in Q1 2025. 35 funds tracked by Wall St. Rank hold RGC as of Q2 2026.

  • Royal Bank of Canada reported no remaining Regencell Bioscience position as of Q2 2026 after selling out during the quarter.
  • Royal Bank of Canada sold 69 Regencell Bioscience shares in Q2 2026, an estimated $2K.
  • Royal Bank of Canada first reported a position in Regencell Bioscience in Q1 2025 and held it in 2 quarters.
  • Royal Bank of Canada's Regencell Bioscience position peaked at $30K in Q1 2025.
  • 35 funds tracked by Wall St. Rank held Regencell Bioscience as of Q2 2026.

Based on Royal Bank of Canada's 13F filing for Q2 2026, filed 14 Aug 2026.